Pathogenic mutations of the Leucine-Rich Repeat Kinase 2 (LRRK2) enzyme are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism. Mayo Clinic researchers were the first to identify this association and have gone on to develop an in-depth understanding of LRRK2 function as well as numerous tools to help identify therapeutic agents to modulate LRRK2 activity. Mayo has a high level of interest in partnering with a group to use our knowledge and tools to develop therapeutic agents against LRRK2 for treatment of Parkinson’s Disease.
Knowledge, assays, and models to develop therapeutic inhibitors of LRRK2 for treatment of Parkinson’s Disease.
Stage of Development
Mayo has developed numerous cell lines, antibodies, and animal models related to LRRK2 including: antibodies (monoclonal and polyclonal), LRRK2 knockout mice, human LRRK2 transgenic mice (wildtype and various mutants), and inducible transgenic mice (LRRK2 mutants). In addition, Mayo has developed a high-throughput cell-based assay for screening for inhibitors of LRRK2.
Dachsel et al. Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease. Mech Ageing Dev. 2010 Mar;131(3):210-4.
Dachsel et al. Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord. 2007 Oct;13(7):382-5.
Mata et al. LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci.2006 May;29(5):286-93.